Health Care · Surgical & Medical Instruments & Apparatus

SOLV Solventum SEC Filings & Insider Trading Activity 2026

company
CIK 196473880 filings
S&P 500

SOLV at a glance

Solventum (SOLV, SEC CIK 1964738) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Solventum (SOLV) reported revenue of $8.3 billion (up 0.9% from FY2024) and net income of $1.6 billion. Diluted EPS was $8.88.
  • As of September 30, 2026, 46 institutional investment managers tracked by SignalX reported holding Solventum (SOLV) shares worth $5.4 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$8.3B
+0.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
46 funds
$5.4B · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
  • Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
  • Best segment: Health Information Systems, operating margin 36.5% vs 33.0%, sales +4.1% to $1,360M; worst: MedSurg margin 16.8% vs 19.1%, despite 3.9% sales growth to $4,817M
  • Investing activities $2,797M inflow (vs -$380M in 2024) driven by ~$4B P&F sale proceeds; financing outflows -$3,057M including $2.0B senior note repayment and $1,070M term loan repayments; cash position $878M at year-end
  • Key risks: tariff impact ~$55M on product costs, ongoing 3M supply agreement mark-ups, debt servicing burden, and brand transition from 3M; no explicit forward guidance provided

Risk Factors

  • 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
  • $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
  • U.S.-China trade tensions and tariffs actively impacting Solventum and suppliers; further escalation cited as material risk to global operations
  • AI-enabled new entrants threatening Health Information Systems segment specifically; failure to match competitor AI integration risks customer loss
  • PFAS indemnification from 3M expires after 2025 product sales; ongoing PFAS use in components (wound therapy, temp management devices) creates unindemnified regulatory and litigation exposure

Business Overview

  • Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
  • Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
  • Still separating from 3M parent: actively transitioning off 3M infrastructure under Transition and Distribution Agreement and Transition Contract Manufacturing Agreement, a key ongoing operational risk
  • R&D team of ~2,000 employees; sales presence in 90+ countries with ~40% of workforce having 10+ years tenure, signaling stable legacy talent base during post-spin transition
  • U.S. Supreme Court ruled Feb 20, 2026 that IEEPA does not authorize presidential tariffs: Solventum explicitly flagged potential tariff recovery but stated financial impact "cannot be reasonably estimated," a rare forward-looking legal disclosure embedded in the business section

AI summary of the SOLV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added strategic risk: health information systems review may fail to produce or complete a strategic alternative
  • Most material update: review creates customer and employee uncertainty while diverting management attention
  • Operational risk: review-related costs may arise regardless of transaction success
  • Financial risk: unsuccessful alternatives could adversely affect cash flows

Management Discussion & Analysis

  • Revenue $1,949M, down 7.0% YoY from $2,096M, reflecting ERP-related customer destocking
  • Operating margin 3.5% vs 80.6% YoY, with $1.5B prior-year business-sale gain
  • Best segment Health Information Systems: sales up 3.3%, operating margin 41.7% vs 38.8%
  • Worst segment Dental Solutions: sales down 6.7%, operating margin 20.1% vs 25.7%
  • Cash $451M vs $878M at December 31, 2025, with $118M of $120M tariff refunds recovered

AI summary of the SOLV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Solventum reported third-quarter 2026 financial results on November 5, 2026
  • Detailed operating results, financial metrics, and management commentary are in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 sales $1.949B, down 7.0% reported and 2.8% organically, reflecting the expected 630 bps ERP-related order reversal
  • Adjusted EPS $1.45, down 3.6%, while GAAP EPS fell to $(0.07) from $7.22 due largely to prior-year business-sale gains
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Solventum reported second-quarter 2026 financial results on August 5, 2026
  • Exhibit 99.1 contains the quarter’s financial results and management commentary for investor review

Item EX-99.1: Item EX-99.1

  • Q2 sales $2.209B, up 2.2% reported and 9.5% organically, with growth across every reportable segment
  • Adjusted EPS $2.55, up 50.9%, but GAAP operating margin fell 170 bps to 8.2% amid legal and separation costs
Filed Aug 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • August 5, 2026 press release covering the material event described under Item 8.01
  • Investor relevance depends on the substantive announcement in Exhibit 99.1

Item 8.01: Other Events

  • Planned separation of Health Information Systems business, advancing Solventum’s portfolio optimization strategy
  • Potential future transaction could reshape business mix and operating focus

AI summaries of SOLV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SOLV

Don't miss the next SOLV filing

  • Alerts as it files. A push when SOLV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SOLV, by share count.
  • Ask anything. An AI agent that reads every SOLV filing and answers with sources.

SOLV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Knight HeatherMNov 17, 2026-
Knight HeatherMNov 17, 2026-
Knight HeatherFNov 17, 2026$86.06
Hanson Bryan CMSep 1, 2026-
Hanson Bryan CMSep 1, 2026-
Hanson Bryan CFSep 1, 2026$90.95
Zieselman Neil CraigAAug 17, 2026-
Harris Bernard A JrAMay 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$8.3B$8.3B
Gross Profit-$4.6B$4.5B
Operating Income-$1.0B$2.2B
Net Income-$479.0M$1.6B
Gross Margin-55.6%53.5%
Op. Margin-12.6%26.2%
Net Margin-5.8%18.7%
Balance Sheet
Total Assets$13.9B$14.5B$14.3B
Equity-$3.0B$5.0B
ROE-16.2%30.8%
Per Share
EPS-$2.76$8.88
Cash Flow
Operating CF-$1.2B$369.0M
CapEx$290.0M$380.0M$379.0M

Source: XBRL data in Solventum (SOLV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SOLV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SOLV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202646$5.37B
Q2 202649$4.59B
Q1 202646$3.90B
Q4 202545$4.61B
Q3 202545$4.34B
Q2 202540$4.25B
Q1 202541$3.62B
Q4 202436$2.89B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 348 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SOLV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Sep 3, 2026--
4Aug 18, 2026--
8-KAug 5, 2026Analysis-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
8-KJul 20, 2026Analysis-
8-KJun 5, 2026Analysis
8-KMay 27, 2026Analysis
8-KMay 20, 2026Analysis
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 15, 2026-
4May 15, 2026-
4May 15, 2026-
4May 15, 2026-

Related Health Care companies

All Health Care →

SOLV SEC filings: frequently asked questions

Which institutions hold SOLV stock?

As of September 30, 2026, the largest Solventum (SOLV) holders among the 13F filers tracked by SignalX were BlackRock ($842.4 million), Vanguard Capital Management LLC ($835.4 million), Trian Fund Management ($726.1 million), Vanguard Portfolio Management LLC ($546.7 million), State Street Corp ($495.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SOLV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Solventum (SOLV) reported revenue of $8.3 billion (up 0.9% from FY2024) and net income of $1.6 billion. Diluted EPS was $8.88. The figures come from the XBRL data in the 10-K.

What are the main risks in SOLV's latest 10-K?

In the 10-K filed February 27, 2026, Solventum (SOLV) flagged: 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability. $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility. (AI summary of the Risk Factors section.)

What did SOLV report in its latest 8-K?

Solventum (SOLV) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Solventum reported third-quarter 2026 financial results on November 5, 2026.

What are the latest SOLV SEC filings?

Solventum (SOLV) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.

What is SOLV's SEC CIK number?

Solventum (SOLV)'s SEC Central Index Key (CIK) is 1964738. EDGAR lists every SOLV filing under that number.

Ask anything about SOLV

The research agent reads SOLV's filings, financials, insider trades and 13F holders, then answers with sources.